Publicaciones en colaboración con investigadores/as de University of California, San Francisco (77)

2024

  1. A road map for the treatment of pediatric diffuse midline glioma

    Cancer Cell

  2. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

2023

  1. Biallelic TET2 mutations confer sensitivity to 5′-azacitidine in acute myeloid leukemia

    JCI Insight, Vol. 8, Núm. 2

  2. Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways

    Cancer Discovery, Vol. 13, Núm. 11, pp. 2370-2393

  3. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)

    Leukemia

  4. Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance

    Nature Reviews Gastroenterology and Hepatology, Vol. 20, Núm. 7, pp. 462-480

  5. Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial

    Nature Medicine, Vol. 29, Núm. 6, pp. 1370-1378

  6. Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer

    Nature Communications, Vol. 14, Núm. 1

  7. TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory

    Cancer Cell, Vol. 41, Núm. 11, pp. 1911-1926.e8

  8. Translational considerations for immunotherapy clinical trials in pediatric neuro-oncology

    Neoplasia (United States), Vol. 42

2022

  1. A diabetic milieu increases ACE2 expression and cellular susceptibility to SARS-CoV-2 infections in human kidney organoids and patient cells

    Cell Metabolism, Vol. 34, Núm. 6, pp. 857-873.e9

  2. Comparison of symptomatic and asymptomatic infections due to severe acute respiratory coronavirus virus 2 (SARS-CoV-2) in San Francisco long-Term care facilities

    Infection Control and Hospital Epidemiology

2021

  1. Crisis decision-making at the speed of COVID-19: Field report on issuing the first regional shelter-in-place orders in the United States

    Journal of Public Health Management and Practice, Vol. 27, pp. S19-S28

  2. DNGR-1 limits Flt3L-mediated antitumor immunity by restraining tumor-infiltrating type i conventional dendritic cells

    Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 5

  3. Lessons from Mass-Testing for Coronavirus Disease 2019 in Long-Term Care Facilities for the Elderly in San Francisco

    Clinical Infectious Diseases, Vol. 72, Núm. 11, pp. 2018-2020

  4. The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma

    Transplantation and Cellular Therapy, Vol. 27, Núm. 10, pp. 807-816

  5. The Pretreatment Gut Microbiome Is Associated With Lack of Response to Methotrexate in New-Onset Rheumatoid Arthritis

    Arthritis and Rheumatology, Vol. 73, Núm. 6, pp. 931-942

2020

  1. Early COVID-19 Successes in Skilled Nursing Facilities in San Francisco

    Journal of the American Geriatrics Society

  2. The Mir181ab1 cluster promotes KRAS-driven oncogenesis and progression in lung and pancreas

    Journal of Clinical Investigation, Vol. 130, Núm. 4, pp. 1879-1895

2019

  1. Antitumor activity of an engineered decoy receptor targeting CLCF1–CNTFR signaling in lung adenocarcinoma

    Nature Medicine, Vol. 25, Núm. 11, pp. 1783-1795